Covidien PLC (NYSE:COV)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued on Monday, AnalystRatings.NET reports. They currently have a $67.00 target price on the stock. Zacks‘ price objective indicates a potential upside of 4.95% from the company’s current price.
Covidien PLC (NYSE:COV) traded up 0.25% on Monday, hitting $64.00. 1,174,398 shares of the company’s stock traded hands. Covidien PLC has a one year low of $49.0071 and a one year high of $65.38. The stock’s 50-day moving average is $62.59 and its 200-day moving average is $60.10. The company has a market cap of $29.440 billion and a P/E ratio of 17.67.
Covidien PLC (NYSE:COV) last posted its quarterly earnings results on Friday, November 8th. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.90 by $0.01. The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.56 billion. During the same quarter in the prior year, the company posted $1.02 earnings per share. The company’s quarterly revenue was up 2.4% on a year-over-year basis. Analysts expect that Covidien PLC will post $4.00 EPS for the current fiscal year.
COV has been the subject of a number of other recent research reports. Analysts at Needham & Company raised their price target on shares of Covidien PLC from $69.00 to $74.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Covidien PLC from $72.00 to $68.00 in a research note to investors on Monday, September 16th. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Covidien PLC presently has an average rating of “Buy” and an average price target of $70.71.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.